Innovations In Clinical Neuroscience

MAR-APR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 22 of 55

23 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE March-April 2018 • Volume 15 • Number 3–4 R E V I E W and sleep disturbance following traumatic brain injury—their nature, causes, and potential treatments. J Head Trauma Rehabil. 2012;27(3):224–33. 8. Dopp JM, Phillips BG. Sleep–Wake Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach, 10e. New York, NY: McGraw-Hill Education; 2017. 9. Kaiser PR, Valko PO, Werth E, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology. 2010;75(20):1780–5. 10. Schwartz JRL. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85. 11. Cheng J, Groninger H. Modafinil #259. J Palliat Med. 2012;15(12):1388–9. 12. Elovic E. Use of provigil for underarousal following TBI. J Head Trauma Rehabil. 2000;15(4):1068–71. 13. Jenkins PO, Mehta MA, Sharp DJ. Catecholamines and cognition after traumatic brain injury. Brain. 2016;139(9):2345–71. 14. Huang C-H, Huang C-C, Sun C-K, et al. Methylphenidate on cognitive improvement in patients with traumatic brain injury: a meta-analysis. Curr Neuropharmacol. 2016;14(3):272–81. 15. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–502. 16. Tembe DV, Dhavale A, Desai H, et al. Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: A randomized double blind multicentric clinical trial. Neurol Res Int. 2011;2011. 17. Kumar R. Approved and investigational uses of modafinil: An evidence-based review. Drugs. 2008;68(13):1803–39. 18. Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol. 2012;27:e2012007. 19. Carstairs SD, Urquhart A, Hoffman J, et al. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol. 2010;6(3):307–10. 20. Red Book Online{®} System (electronic version). Greenwood Village, Colorado: Truven Health Analytics; 2017. 21. Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil. 2008;23(1):52–63. 22. Lillicrap T, Krishnamurthy V, Attia J, et al. Modafinil in debilitating fatigue after stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial. Trials. 2016;17(1):410. 23. Castriotta RJ, Atanasov S, Wilde MC, et al. Treatment of sleep disorders after traumatic brain injury. J Clin sleep Med. 2009;5(2):137– 44. 24. Brioschi A, Gramigna S, Werth E, et al. Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. Eur Neurol. 2009;62(4):243–9. 25. Tcheremissine OV, Rachal JC. Modafinil augmentation therapy in patient with traumatic brain injury. Innov Clin Neurosci. 2017;14(3–4):11. 26. Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. Sleep. 2014;37(3):483–7. 27. Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis—a brief review. J Neurol Sci. 2012;323(1–2):9–15. ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2018